Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serplulimab Neoadjuvant Therapy for ESCC
NCT06388135Phase 4Not yet recruiting
- Start
- May 2024
- Primary completion
- May 2026
- Modality
- Immune Checkpoint Inhibitors
01
Overview
A Phase 4 trial of serplulimab in Esophageal Squamous Cell Carcinoma (ESCC). Planned start May 2024; status: not yet recruiting.
02
Drugs
serplulimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT06388135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06388135.